Uniqure (NASDAQ:QURE) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Saturday.
A number of other research analysts have also recently commented on the stock. HC Wainwright set a $35.00 price target on shares of Uniqure and gave the stock a “buy” rating in a report on Thursday. Zacks Investment Research cut shares of Uniqure from a “hold” rating to a “sell” rating in a report on Saturday, February 24th. ValuEngine upgraded shares of Uniqure from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Janney Montgomery Scott began coverage on shares of Uniqure in a report on Wednesday, January 3rd. They issued a “buy” rating and a $25.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. Uniqure has a consensus rating of “Hold” and a consensus price target of $20.75.
Uniqure (NASDAQ:QURE) opened at $21.59 on Friday. The company has a quick ratio of 3.64, a current ratio of 8.46 and a debt-to-equity ratio of 0.22. The company has a market cap of $684.06, a PE ratio of -7.34 and a beta of 0.09. Uniqure has a 1-year low of $4.72 and a 1-year high of $27.19.
In related news, Director David Schaffer sold 2,878 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $18.53, for a total value of $53,329.34. Following the completion of the sale, the director now directly owns 15,314 shares of the company’s stock, valued at $283,768.42. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Deventer Sander Van sold 5,985 shares of the company’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $18.53, for a total transaction of $110,902.05. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 41,510 shares of company stock worth $815,776. Company insiders own 0.73% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. lifted its stake in Uniqure by 660.1% in the fourth quarter. Macquarie Group Ltd. now owns 532,049 shares of the biotechnology company’s stock worth $10,423,000 after acquiring an additional 462,049 shares during the period. Perceptive Advisors LLC lifted its stake in Uniqure by 0.8% in the fourth quarter. Perceptive Advisors LLC now owns 1,047,950 shares of the biotechnology company’s stock worth $20,529,000 after acquiring an additional 7,831 shares during the period. Two Sigma Investments LP purchased a new stake in Uniqure in the fourth quarter worth about $2,721,000. Two Sigma Advisers LP purchased a new stake in Uniqure in the fourth quarter worth about $476,000. Finally, Ellington Management Group LLC purchased a new stake in Uniqure in the fourth quarter worth about $237,000. 44.05% of the stock is owned by institutional investors.
WARNING: “Uniqure (QURE) Stock Rating Lowered by BidaskClub” was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.thelincolnianonline.com/2018/03/19/uniqure-qure-stock-rating-lowered-by-bidaskclub.html.
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.